Myth: “More CFU = Better Probiotic”

Evidence Reviews · July 29, 2026 · 6 min read

It is the number that jumps off the label in bold, oversized font: 50 BILLION CFU. 100 BILLION CFU. 200 BILLION CFU. The implicit message is unmistakable — bigger number, better product. More bacteria, more benefit. It feels intuitive. It is also, in most cases, meaningless.

This myth persists because CFU count is the one metric that is easy to print, easy to compare, and easy to misunderstand. Let us dismantle it with evidence.

What CFU Actually Measures

CFU — colony-forming unit — counts the number of viable bacterial cells in a sample that can reproduce under laboratory culture conditions. It is a legitimate microbiological measurement. The problem is not the measurement itself; it is what manufacturers and consumers infer from it.

A CFU count tells you:

• How many living cells were present at the time and under the conditions of testing

A CFU count does not tell you:

• Which species or strains those cells belong to
• Whether those strains have any evidence of efficacy in dogs
• How many cells will survive stomach acid, bile salts, and pancreatic enzymes
• Whether the count was measured at manufacture or at expiry
• Whether the product was stored correctly during shipping and warehousing
• Whether the organisms can colonize, even transiently, the canine intestinal mucosa

In other words, CFU is a necessary-but-insufficient quality parameter. It confirms that something alive is in the capsule. It says nothing about whether that something will help your dog.

The JAVMA 2019 Evidence

A landmark randomized controlled trial published in the Journal of the American Veterinary Medical Association (2019) directly tested the “more is better” assumption. The study enrolled client-owned dogs presenting with acute uncomplicated diarrhea and randomized them to receive either:

• A high-CFU multi-strain probiotic (total count exceeding 50 billion CFU per dose, containing six generic strains)
• A lower-CFU single-strain product (Enterococcus faecium SF68, approximately 1 billion CFU per dose) with extensive published canine evidence
• Placebo

Key Findings

• Time to resolution of diarrhea was significantly shorter in the E. faecium SF68 group compared to placebo (p < 0.01).
• The high-CFU multi-strain group showed no statistically significant advantage over placebo for primary endpoints.
• Fecal microbiome analysis showed transient engraftment of E. faecium SF68 in the low-CFU group. The high-CFU group showed minimal engraftment of any administered strains.
• No dose-response relationship was observed between total CFU administered and clinical improvement.

The implication is stark: a well-characterized strain at 1 billion CFU outperformed a poorly characterized blend at 50+ billion CFU. The number on the box was inversely related to actual efficacy.

Why High CFU Counts Are Often Misleading

1. The “At Manufacture” Trick

Many products list CFU “at time of manufacture.” Bacteria die during storage. A product labeled “100 billion CFU at manufacture” may contain 30 billion — or 5 billion — by the time it reaches your shelf six months later. Reputable products guarantee CFU at expiry. If the label does not specify, assume the number is inflated.

2. Strain Redundancy

A “15-strain” formula sounds impressive. But if those 15 strains are closely related subspecies of Lactobacillus acidophilus with overlapping mechanisms, you have not gained 15 different benefits. You have gained marketing copy. Strain diversity matters only when each strain contributes a distinct, evidenced mechanism.

3. Gastric Attrition

The canine stomach operates at pH 1-2 during digestion. Unprotected bacteria face a 90-99.9% kill rate in gastric transit. A product delivering 100 billion CFU in the capsule may deliver 100 million — or fewer — to the small intestine. Enteric coating, microencapsulation, or inherently acid-resistant strains (like Bacillus spore-formers) address this. Raw CFU count does not.

4. The Colonization Fallacy

Most probiotic strains do not permanently colonize the canine gut. They transit, exert effects during passage, and are cleared within 7-14 days of discontinuation. More CFU does not change this pharmacokinetic reality. What matters is whether the strain produces relevant metabolites or immune signals during transit, not whether it establishes a permanent colony.

5. Manufacturing Quality Varies

An independent analysis published in the Journal of Veterinary Pharmacology and Therapeutics (2022) tested 25 commercial canine probiotic products. Only 11 of 25 (44%) contained viable counts within one log of the label claim. Three products contained no viable organisms of the listed species. The highest-CFU product in the study was among those that failed verification.

What Actually Determines Probiotic Efficacy

If CFU count is not the answer, what is? The evidence points to a hierarchy of importance:

1. Strain identity and evidence base. A strain with published canine RCTs demonstrating a specific outcome (reduced diarrhea duration, improved fecal score, reduced inflammatory markers) is worth more than any CFU number.
2. Viability at point of use. CFU guaranteed at expiry, verified by third-party testing, with appropriate storage instructions.
3. Delivery system. Enteric coating, microencapsulation, or spore-forming organisms that survive gastric transit.
4. Adequate (not maximal) dose. Most published canine trials use 1-10 billion CFU per day. There is no evidence that exceeding this range improves outcomes for standard indications.
5. Appropriate indication. The strain must match the clinical goal. A strain studied for diarrhea may have zero evidence for immune support or oral health.

The Marketing Psychology

Why does the CFU arms race continue? Because it works commercially. Consumers anchor on the largest visible number. “100 billion” feels more powerful than “5 billion” the same way “1000mg” feels more potent than “500mg” on a supplement shelf. Manufacturers who invest in strain research and clinical trials compete against manufacturers who invest in larger fonts.

This is not unique to pet supplements. The human probiotic market exhibits identical dynamics. But dogs cannot report subjective improvement, making objective evidence even more critical in the veterinary context.

How to Evaluate a Probiotic Product (Beyond CFU)

• Ask for strain designations. “Lactobacillus acidophilus NCFM” is a strain. “Lactobacillus acidophilus” is a species. “Lactobacillus” is a genus. The more specific the label, the more accountable the manufacturer.
• Ask for published studies. Ideally, peer-reviewed canine trials. At minimum, extrapolation from well-designed human trials with the same strain.
• Check the guarantee language. “CFU at expiry” or “through best-by date” is the standard. “At manufacture” is a red flag.
• Look for third-party verification. NASC Quality Seal, NSF certification, or independent lab COAs confirm that what is on the label is in the product.
• Consider the format. Powders, chews, capsules, and liquids have different stability profiles. A 50-billion CFU chew stored in a warm warehouse may deliver less than a 5-billion CFU refrigerated capsule.

The Bottom Line

CFU count is a quality-control parameter, not an efficacy metric. It answers the question “are there living bacteria in this product?” It does not answer “will this product help my dog?” The JAVMA 2019 trial and subsequent research make clear that strain selection, delivery technology, and clinical evidence matter far more than raw numbers.

The next time you see “200 BILLION CFU” in neon letters on a supplement label, treat it as marketing — not medicine. Then flip the box and look for what actually matters: strain names, published evidence, and third-party verification.